logo

For the Inventor, By the Inventor

Planegg, Germany

Morphosys Ag


USPTO Granted Patents = 92

% Expired Patents = 27.2



Trademarks = 20

Forward Citations = 1,040

Loading Chart...
Loading Chart...

125 inventors (with patents filed for the assignee):

goldMedal Josef Prassler (12 out of 20 patents)

silverMedal Jan Endell (11 out of 14 patents)

bronzeMedal Michael Tesar (11 out of 15 patents)

4.  Thomas Tiller (9 out of 10 patents)

5.  Rainer Boxhammer (8 out of 11 patents)

6.  Markus Enzelberger (8 out of 11 patents)

7.  Peter Pack (8 out of 8 patents)

8.  Stefanie Urlinger (7 out of 16 patents)

9.  Mark Winderlich (7 out of 8 patents)

10.  Stefan Steidl (7 out of 8 patents)

11.  Yvonne Stark (7 out of 7 patents)

12.  Achim Knappik (7 out of 8 patents)

13.  Liming Ge (7 out of 7 patents)

14.  Ute Jäger (6 out of 6 patents)

15.  Elisabeth Thomassen-Wolf (5 out of 5 patents)


Core Competencies:
Therapeutic Antibodies
Anti-CD38
IL-17C
GM-CSF
Multiple Myeloma
Rheumatoid Arthritis
Peptide Libraries
Canine Antibody Libraries
Humanized Antibodies
Antibody Fragments
M-CSF
Bacteriophage Particles

92 patents:

1. 12760063 - ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY (2026-10-13),
2. 12747292 - ANTI-TUMOR COMBINATION THERAPY COMPRISING ANTI-CD19 ANTIBODY AND GAMMA DELTA T-CELLS (2026-09-29),
3. 12698326 - ANTI-CD19 ANTIBODY FORMULATIONS (2026-08-04),
4. 12631639 - METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS (2026-05-19),
5. 12018072 - Antibodies specific for human complement C5A receptor (C5AR) (2024-06-25),
6. 11987621 - Antibodies for IL-17C (2024-05-21),
7. 11939395 - Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38 (2024-03-26),
8. 11702463 - Canine antibody libraries (2023-07-18),
9. 11618789 - Clinical assessment of M-protein response in multiple myeloma (2023-04-04),
10. 11591406 - Treatment for multiple myeloma (MM) (2023-02-28),
11. 11542329 - Antibodies targeting Glycoprotein VI (2023-01-03),
12. 11472880 - Humanized antibodies for CD3 (2022-10-18),
13. 11352620 - Peptide libraries (2022-06-07),
14. 11352423 - Anti-CD19 antibody formulations (2022-06-07),
15. 11254734 - Fab molecules with a rodent hinge region and a non-rodent CH1 region (2022-02-22),
Company Overview
Morphosys AG is a biotechnology company based in Planegg, Germany, specializing in the development of therapeutic antibodies. The company focuses on innovative treatments for various diseases, including multiple myeloma and rheumatoid arthritis, utilizing advanced technologies such as peptide libraries and canine antibody libraries. Morphosys is dedicated to harnessing the potential of its proprietary anti-CD38 and IL-17C antibodies to address unmet medical needs and improve patient outcomes in the field of immunotherapy.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Morphosys Ag USPTO Patent Assignee Logo
92 Patents

#1 in Planegg

#640 in Germany

#8,380 in the World

Planegg, DE
Planegg, Germany

Morphosys Ag

Forward Citations = 1,040

125 inventors:

goldMedal Josef Prassler (12 out of 20 patents)

silverMedal Jan Endell (11 out of 14 patents)

bronzeMedal Michael Tesar (11 out of 15 patents)

4.  Thomas Tiller (9 out of 10 patents)

5.  Rainer Boxhammer (8 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Morphosys Ag. Retrieved from https://idiyas.com/company/morphosys-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…